Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis

摘要: Background: Many clinical trials have shown the efficacy of aromatase inhibitors (AIs) in management breast cancer (BC). There is growing evidence that CYP19A1 single-nucleotide polymorphisms (SNPs) are associated with response (CR) and adverse effects (AEs) among BC patients treated AIs. The aim this study was to analyze association between AI treatment patients. Methods: A systematic review performed MEDLINE, EMBASE, LILACS. meta-analysis conducted compare variants Results: total 12 studies were included final analysis. significant variation populations studied SNPs outcomes investigated. only possible for evaluation SNP rs4646 vs. wild-type variant respect time progression (TTP) metastatic AI. TTP significantly increased compared gene (hazard ratio (HR) = 0.51 [95 % confidence interval (CI), 0.33–0.78], P 0.002). Seven analyzed AEs different CYP19A1. Although there a statistically musculoskeletal events (rs934635, rs60271534, rs700518rs, haplotype M_3_5) vasomotor symptoms rs1694189, rs7176005, M_5_3) individual studies, similar associations not observed further studies. No rs4646, rs10046, rs727479, rs1062033 found. Conclusions: These findings suggest presence may be predictive factor benefit BC. on most often detected suggesting longer-term will better clarify these associations. Additional needed value other whether genotyping should used guide treatment.